The Effect of Purple Sweet Potato (PSP)-Juice on Liver Enzymes and Blood Pressure

NCT00962195 | Completed

• 1 other identifier: P8604
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Purple Sweet Potato juice (PSP-juice) is a juice based on purple-fleshed sweet potato concentrate, containing a high level of anthocyanins. Purple-fleshed sweet potatoes have attracted attention to industry and scientists due to multiple physiological functions such as radical-scavenging, ACE-inhibitory and α-glucosidase inhibitory activities in vitro, and also hepato-protective, antihypertensive and antihyperglycemic effects in vivo. Previous studies in Japanese subjects showed potential beneficial effects of PSP beverages on liver function and blood pressure in volunteers with impaired hepatic function and/or hypertension. The main objective of this study is to examine the effect of PSP-juice on liver enzymes and blood pressure. The secondary objective is to examine the effects of PSP-juice juice on insulin resistance.

Conditions

Health; Blood Pressure; Liver Function; Insulin Resistance

Keywords

health; blood pressure; liver enzymes; insulin resistance

Outcome Measures

Primary Outcomes (1)

• liver enzymes

  every 2 weeks during 8-weeks intervention

Secondary Outcomes (2)

• blood pressure

  every 2 weeks during 8-weeks intervention

• insulin resistance

  every 2 weeks during 8-weeks intervention

Study Arms (2)

purple sweet potato juice

EXPERIMENTAL

Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks

Dietary Supplement: purple sweet potato (PSP)-juice

Control juice

PLACEBO COMPARATOR

Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks

Dietary Supplement: purple sweet potato (PSP)-juice

Interventions

purple sweet potato (PSP)-juice DIETARY_SUPPLEMENT

Daily oral intake of 3x 125 ml of PSP-juice or control juice

Control juice; purple sweet potato juice

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy as assessed by the: Health and Lifestyle Questionnaire, results of the pre study laboratory tests in blood
• Males/Females aged 40-70 years (boundaries included) at Day 01 of the study
• Body Mass Index (BMI) 25-35 (boundaries included) kg/m2
• Liver enzymes above reference values GGT ≥ 45 IU/L (for males) and ≥ 35 IU/L (for females), and/or ASAT ≥ 45 IU/L (for males and females), and/or ALAT ≥ 50 IU/L (for males) and ≥ 40 IU/L (for females)
• Blood pressure (automated measurements at site): systolic blood pressure 130-159 mm Hg (boundaries included) and/or diastolic blood pressure 85-99 mm Hg (boundaries included)
• Voluntary participation
• Having given written informed consent
• Willing to comply with the study procedures
• Willing to give up blood/plasma donation during the study
• Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
• Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.

You may not qualify if:

• Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
• Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
• Having a history of medical or surgical events that may significantly affect the study outcome
• Any concomitant medication, with the exception of occasional use of a paracetamol tablet, that may influence the outcome of the study (to be judged by the medical investigator)
• Food allergy/intolerance
• Alcohol consumption \> 28 units/week for males and \> 21 units/week for females
• Smoking \> 10 cigarettes per day
• Reported unexplained weight loss or gain of \> 2 kg in the month prior to the pre study screening
• Reported slimming or medically prescribed diet
• Participation in night shift work
• Pregnant or lactating or wishing to become pregnant in the period of the study
• Personnel of TNO Quality of Life, their partner and their first and second degree relatives
• Not having a general practitioner
• Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Sponsors & Collaborators

• TNO: lead
• Yakult Honsha Co., LTD: collaborator

Study Sites (1)

TNO Quality of Life

Zeist, Utrecht, Netherlands

Location

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Esther Boelsma, PhD

  TNO

  PRINCIPAL INVESTIGATOR

• Ineke Klopping-Ketelaars, PhD

  TNO

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: August 18, 2009
• First Posted: August 19, 2009
• Study Start: June 1, 2009
• Primary Completion: December 1, 2009
• Study Completion: December 1, 2009
• Last Updated: April 14, 2010

Record last verified: 2010-04

Locations

NL (1)